A federal securities class action has been filed against Ultragenyx Pharmaceutical Inc., alleging that the company and its executives made false or misleading statements regarding the reliability of data from its Phase III Orbit study on setrusumab for Osteogenesis Imperfecta. The complaint claims Ultragenyx failed to disclose risks related to basing interim analysis benchmarks on earlier Phase II results that lacked a placebo control group. Following these revelations, Ultragenyx’s stock price fell by more than 42%. Investors who purchased Ultragenyx securities between August 3, 2023 and December 26, 2025 have until April 6, 2026 to seek lead plaintiff status in the case.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602160935NEWSFILECNPR____20260216_283912_1) on February 16, 2026, and is solely responsible for the information contained therein.